Viral Myocarditis
Receptors That Bridge the Cardiovascular With the Immune System?

Peter P. Liu, M. Anne Opavsky

Viral myocarditis exhibits different clinical phenotypes depending on the age of the patient. In pediatric patients, viral myocarditis can present as acute heart failure and cardiogenic shock, and in older patients, it often presents as chronic, slowly progressive heart failure and dilated cardiomyopathy. The severity of viral myocarditis is determined by a delicate balance between the viral infection and the inflammatory response that is engendered in the host.

The commonest viral causes of human myocarditis include coxsackievirus B group and adenovirus. It is no accident that these two viruses emerged as the commonest etiological agents of myocarditis. Recent elegant work by Bergelson et al. demonstrated that both of these viruses share a common cell surface receptor—coxsackie-adenoviral receptor (CAR).

CAR is a 46-kDa member of the immunoglobulin (Ig) superfamily, featuring the Ig loops maintained by disulphide bonds between appropriately positioned cysteines. The extracellular domain is the key functional component for coxsackievirus internalization. CAR also serves as an attachment receptor for adenovirus. However, the natural function and regulation of CAR are still relatively unknown.

The efficiency in targeting the host cell by coxsackievirus and adenovirus depends on their distinct coreceptors. Coxsackievirus B (CVB) uses the complement deflecting protein decay accelerating factor (DAF, CD55) as its coreceptor, whereas adenovirus uses integrin αvβ3 and αvβ5 as its coreceptors. DAF as a coreceptor serves an important function by significantly increasing the binding efficiency of coxsackievirus onto the DAF-CAR receptor complex to facilitate internalization by CAR.

Role of the Receptors in Viral Myocarditis
Myocarditis is both a viral and inflammatory disease. The virus uses the T and B lymphocytes as part of its trafficking in the host, increasing viral load in the heart (a classic Trojan Horse scenario). The localization of the virus in the heart determines the subsequent development of the inflammatory foci in the heart, as the immune system is activated trying to clear the virus. Therefore, the ability for the virus to enter the target cells such as the myocyte will very much influence the subsequent course of the disease. Hence, information on the receptor repertoire in the myocytes, as studied by Ito et al. and reported in this issue of Circulation Research, contributes significantly to our understanding of the pathogenesis of the disease and the corresponding clinical phenotype.

In the case of coxsackieviral myocarditis, the internalization receptor (CAR) collaborates with the attachment coreceptor (DAF), probably through a stereochemical interaction (Figure). DAF facilitates the binding of the virus onto the receptor-coreceptor complex, and CAR is responsible for the internalization of the virus to permit subsequent viral replication. As noted by Ito et al., DAF and CAR are part of an immune family of receptors, suggesting an interaction between cardiovascular development and immune signaling pathways. Paradoxically, these immune molecules such as CAR when expressed in the cardiovascular system are used by an external infectious agent as portal of entry into the myocyte.

How Are the Receptors Regulated?
How receptors such as CAR are regulated will be important in understanding the kinetics of the disease. It is of interest that CAR is expressed in higher quantities in younger hearts than older hearts, suggesting a developmental role. In addition, it may also explain the higher propensity of coxsackieviral infections in newborns and young children with a more clinically acute disease. The most interesting aspect of the present study suggested that the CAR receptor can be induced under immunological activation. In the present study, this was generated through an autoimmune mechanism by immunizing with myosin. The myosin autoimmune murine model is a good general noninfectious model to study the inflammatory component of myocarditis.

Thus, immune stimulation increases expression of the CAR receptor, making the target organ even more susceptible to further uptake of the virus. As suggested by Ito et al., CAR may in addition play a role in cell-cell communication and may further enhance the inflammatory interaction between immune cells and the myocyte and the subsequent repair process.

Because the immune system is often activated by cytokine signaling pathways, CAR may also be regulated through this mechanism. It is therefore of interest that when the immune system is specifically inhibited through targeted knockout strategy, such as with CD4+/−/CD8−/− null transgenics or through knockout of the tyrosine kinases such as p56lck−/−, associated signal amplification pathways, coxsackieviral...
myocarditis is dramatically reduced in severity, without an increase in viral titers. This may be facilitated by a decreased upregulation of CAR, significantly impairing the kinetics of replication of the etiological viral agent.

**Could the Immune-Cardiovascular Linkage Have a Happy Ending?**

Insights into the virus-receptor interaction and its regulation by the immune system, as elucidated by the present study, further enhance our understanding of myocarditis. Inflammation can lead to increased expression of CAR, which in turn may lead to an increase in viral infection and amplify the inflammatory process. This positive feedback loop may point toward novel therapeutic strategies. Specific peptide or non-peptide blockers that interfere with the interaction of the virus with its receptor is one approach. Reduction of specific elements of the inflammatory response may secondarily decrease CAR receptor expression and, in turn, protect the host from viral myocarditis. CAR provides the first example of a unique linkage between the cardiovascular and immune system. It also opens the door to fully explore its scientific implications and develop novel therapeutic opportunities.

**References**

Viral Myocarditis: Receptors That Bridge the Cardiovascular With the Immune System?

Peter P. Liu and M. Anne Opavsky

Circ Res. 2000;86:253-254
doi: 10.1161/01.RES.86.3.253

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/86/3/253

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/